Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)
Phase 2
Terminated
- Conditions
- Hereditary Hemochromatosis
- Interventions
- Procedure: Phlebotomy
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT03203850
- Locations
- 🇨🇭
Novartis Investigative Site, Lugano, Switzerland
Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment
Phase 2
Completed
- Conditions
- Advanced Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT03200717
- Locations
- 🇬🇧
Novartis Investigative Site, Preston, United Kingdom
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066
Phase 2
Completed
- Conditions
- Obesity
- Interventions
- Dietary Supplement: Carbohydrate 50%Dietary Supplement: Carbohydrate 8%Dietary Supplement: Carbohydrate 25%Dietary Supplement: PsylliumDietary Supplement: Carbohydrate 0%Dietary Supplement: Calcium carbonate
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT03198767
- Locations
- 🇺🇸
Novartis Investigative Site, Lincoln, Nebraska, United States
Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication
Phase 2
Completed
- Conditions
- Peripheral Artery Disease (PAD); Intermittent Claudication
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 46
- Registration Number
- NCT03194776
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
Phase 1
Terminated
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT03176264
- Locations
- 🇬🇧
Novartis Investigative Site, Sutton, Surrey, United Kingdom
Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Phase 3
Completed
- Conditions
- Post Menopausal Breast Cancer
- Interventions
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 235
- Registration Number
- NCT03176238
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 106
- Registration Number
- NCT03172936
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇨🇭Novartis Investigative Site, Zurich, Switzerland
Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Phase 2
Completed
- Conditions
- Acute Uncomplicated Plasmodium Falciparum Malaria
- Interventions
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 524
- Registration Number
- NCT03167242
- Locations
- 🇻🇳
Novartis Investigative Site, Binh Phuoc Province, VNM, Vietnam
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1426
- Registration Number
- NCT03158311
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 29
- Registration Number
- NCT03152591
- Locations
- 🇩🇪
Novartis Investigative Site, Freiburg, Germany